Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Hematology & Oncology|February 13, 2010
From basic research to clinical development of MEK1/2 inhibitors for cancer therapyChristophe Frémin, Sylvain Meloche
International Journal of Hepatology|November 8, 2012
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle ControlJean-Philippe Guégan, Christophe Frémin, Georges Baffet
Journal of Cellular Physiology|April 12, 2007
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cellsAnne Bessard, Christophe Frémin, Frédéric Ezan, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 8, 2016
Isolation of Mouse Embryonic Stem Cell Lines in the Study of ERK1/2 MAP Kinase SignalingMarc K Saba-El-Leil, Christophe Frémin, Sylvain Meloche
Frontiers in Cell and Developmental Biology|July 23, 2016
Redundancy in the World of MAP Kinases: All for OneMarc K Saba-El-Leil, Christophe Frémin, Sylvain Meloche
Molecular Systems Biology|May 29, 2013
Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functionsMathieu Courcelles, Christophe Frémin, Laure Voisin, et al.
Cell Reports|August 4, 2015
Functional Redundancy of ERK1 and ERK2 MAP Kinases during DevelopmentChristophe Frémin, Marc K Saba-El-Leil, Kim Lévesque, et al.
Hepatology (Baltimore, Md.)|March 30, 2007
ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytesChristophe Frémin, Frédéric Ezan, Pierre Boisselier, et al.
International Journal of Cancer|October 10, 2009
RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivoLuc Gailhouste, Frédéric Ezan, Anne Bessard, et al.
Pageof 2